Intelligent Bio posts updated investor presentation

Q: What did INTELLIGENT BIO SOLUTIONS INC. (INBS) announce on August 28, 2026?

INBS furnished an investor presentation describing its business and operations. The presentation was made available to investors on August 28, 2026 and is accessible through the Investors section of the company’s website.

Q: Under which item did INBS provide the presentation in this Form 8-K?

The presentation was provided under Item 7.01 Regulation FD Disclosure, indicating it is being shared to ensure broad public access to information provided to investors.

Q: Where can investors access the INBS August 28, 2026 presentation?

Investors can access the presentation via the Investors section of INBS’s website at www.ibs.inc, as referenced in the Form 8-K.

Q: What exhibits did INBS include with this Form 8-K?

INBS included Exhibit 99.1, the presentation made available on August 28, 2026, and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

INTELLIGENT BIO SOLUTIONS INC. (INBS) furnished an investor presentation under a Regulation FD current report. The company made a presentation about its business and operations available to investors on August 28, 2026, which can be accessed through the Investors section of its website.

The presentation is furnished, not filed, so it is not automatically incorporated into other Securities Exchange Act or Securities Act filings unless specifically referenced there.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Terms

Regulation FD, Emerging growth company, Inline XBRL, furnished and shall not be deemed to be filed

4 terms

Regulation FD regulatory

"Pursuant to Regulation FD, Intelligent Bio Solutions Inc. ... furnishes the presentation"

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Inline XBRL technical

"Cover Page Interactive Data File (embedded within the Inline XBRL document)"

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

furnished and shall not be deemed to be filed regulatory

"is being furnished and shall not be deemed to be “filed”"

FAQ

What did INTELLIGENT BIO SOLUTIONS INC. (INBS) announce on August 28, 2026?

INBS furnished an investor presentation describing its business and operations. The presentation was made available to investors on August 28, 2026 and is accessible through the Investors section of the company’s website.

Under which item did INBS provide the presentation in this Form 8-K?

The presentation was provided under Item 7.01 Regulation FD Disclosure, indicating it is being shared to ensure broad public access to information provided to investors.

Is the INBS investor presentation considered filed with the SEC?

No. INBS states that the information under Item 7.01, including Exhibit 99.1, is being furnished and is not deemed “filed” under the Securities Exchange Act of 1934, unless specifically incorporated by reference elsewhere.

Where can investors access the INBS August 28, 2026 presentation?

Investors can access the presentation via the Investors section of INBS’s website at www.ibs.inc, as referenced in the Form 8-K.

What exhibits did INBS include with this Form 8-K?

INBS included Exhibit 99.1, the presentation made available on August 28, 2026, and Exhibit 104, the Cover Page Interactive Data File embedded within the Inline XBRL document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/28/2026 - 05:21 PM Accepted by SEC EDGAR 08/28/2026 - 05:20 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 28, 2026

INTELLIGENT BIO SOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-39825

82-1512711

(State of

Incorporation)

(Commission

File Number)

(IRS employer

identification no.)

135 West 41st Street, 5th Floor

New York, NY 10036

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (646) 790-5756

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		INBS		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

Pursuant to Regulation FD, Intelligent Bio Solutions Inc. (the “Company”) hereby furnishes the presentation (the “Presentation”) that the Company made available to investors on August 28, 2026, relating to the Company’s business and operations. The Presentation can be accessed by visiting the Investors section of the Company’s website: www.ibs.inc.

The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.

Item 9.01 Financial Statements and Exhibits.

No.		Description
99.1		Presentation made available on August 28, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.